Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625470 | 0.89 | TSHR (0.37) | ARALDH1A1LMNAMAOACYP1A2 | |
| SCHEMBL19626775 | 0.86 | AR (0.46) | ARALDH1A1WDR5MAOAMAOB | |
| SCHEMBL19625473 | 0.84 | ALDH1A1 (0.42) | ALDH1A1LMNANPC1RAB9ACYP1A2 | |
| SCHEMBL19625363 | 0.82 | AR (0.48) | ARALDH1A1LMNANPC1RAB9A | |
| SCHEMBL19625468 | 0.75 | NPC1 (0.47) | ARALDH1A1LMNAMAOANPC1 | |
| SCHEMBL19626783 | 0.75 | TSHR (0.40) | ALDH1A1LMNAMAOANPC1RAB9A | |
| SCHEMBL19626793 | 0.74 | NOTUM (0.52) | ARLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL17626121 | 0.74 | ALDH1A1 (0.40) | ARALDH1A1LMNANPC1RAB9A | |
| SCHEMBL1309929 | 0.72 | PIK3CA (0.47) | ARLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL19625461 | 0.71 | ALDH1A1 (0.43) | ALDH1A1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | AR 281/4885ALDH1A1 1166/4885LMNA 2300/4885 |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | AR 281/4885ALDH1A1 1166/4885LMNA 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.